Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people lose very little weight in week 1 of Mounjaro — and that is entirely normal. The 2.5mg starting dose is a tolerability step, not a therapeutic one; its job is to help your body adjust rather than drive significant fat loss. Real, sustained weight reduction typically builds over the following weeks and months as the dose increases. These are prescription-only medicines and a prescriber decides whether treatment is clinically suitable for you before anything else happens.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The packaging arrived in a plain, unbranded box via DPD, your phone showed the tracking notification, and now the pen is in the fridge. You have taken your first 2.5mg dose and, a few days later, you step on the scales. The number may have barely shifted. You might even be a little heavier if you are holding extra water from a stressful week.
This is not a sign that Mounjaro is not working. The first pen's purpose is adjustment. At 2.5mg, tirzepatide's dual GIP and GLP-1 receptor action is present but deliberately understated, Eli Lilly designed the starting dose to reduce the chance of nausea and other gastrointestinal side effects, not to produce immediate weight loss. The NHS medicines page for tirzepatide is clear that the dose is typically increased by a prescriber in four-week steps up to a clinically appropriate maintenance level.
Any downward movement on the scales during that first week most often reflects eating less because your stomach is unsettled, or simply drinking less fluid. Neither figure tells you much about what the medicine will do over the coming months.
SURMOUNT-1, the pivotal phase-3 trial published in the New England Journal of Medicine, followed 2,539 adults across 72 weeks. At the highest dose, average body-weight reduction reached around 20–21%. That figure accumulated over nearly a year and a half of treatment, with dose increases at every four-week interval. Week 1 data from that trial was never the headline, because it was never the point.
The pattern in clinical practice mirrors this. Appetite suppression tends to become noticeably stronger as the dose increases through 5mg, 7.5mg and beyond. Many people describe week 4 or 5 as the first moment food genuinely felt less compelling. A question our prescribers hear regularly is whether a flat first week means the medicine is not working, it almost never does. Consistent results take consistent titration.
If you are curious about how long Mounjaro takes to work in a broader sense, the honest answer spans months rather than weeks. That is not a failing of the medicine; it reflects how biology actually changes body weight.
Mounjaro week 1 with no weight loss is so common it is practically the norm. Concern is warranted only in specific, different circumstances: if you are experiencing severe or persistent side effects, if you have not been able to tolerate the injection at all, or if several months into a therapeutic dose the scales remain completely static.
Early side effects to be aware of are mostly gastrointestinal, nausea, loose stools, constipation or indigestion. These tend to peak in the first few days after a new dose and fade as the weeks pass. Severe, persistent stomach pain that radiates to the back is different and needs prompt medical attention; the MHRA flagged acute pancreatitis as a known, infrequent but serious risk across GLP-1 medicines in a 2026 Drug Safety Update. That symptom should not be waited out at home.
For most people, though, a quiet first week is the body doing what it is supposed to do. The prescription schedule is built around this. You can read more about how weight loss on Mounjaro progresses as titration continues, or about what to expect if things feel slow at week 2 or week 4.
The medicine does the pharmacological work, but the context around it matters. Protein intake, staying hydrated, and some form of movement (even walking) help preserve muscle mass as weight comes off, which in turn supports long-term results. The appetite reduction that builds through the titration schedule makes it easier to eat less without white-knuckling it, but the quality of what you eat still influences how your body responds.
Cost and access are real considerations too. A transparent breakdown of what private Mounjaro treatment involves is worth reading on our treatment page before starting, so there are no surprises as doses increase. Treatment decisions, including any dose change or what to do if progress stalls, belong with your prescriber, not with a forum or a best guess.
If you have not yet started and want to understand the full picture of Mounjaro as a treatment, or if you are ready to talk to a clinician about whether it is right for you, our prescribers review consultations the same day, a real clinician reads your answers, not an algorithm. Speak to our prescribers to get started.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.